Literature DB >> 11166515

Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin.

M E Liechti1, M A Geyer, D Hell, F X Vollenweider.   

Abstract

Prepulse inhibition (PPI) of the acoustic startle response is an operational measure of sensorimotor gating that can be assessed in animals and in humans. Serotonin releasers such as MDMA disrupt PPI and reduce startle habituation in rodents. These effects are prevented by pretreatment with selective serotonin uptake inhibitors, indicating that the effect of MDMA on startle plasticity is largely due to carrier-mediated release of serotonin from presynaptic terminals. In contrast, MDMA has been shown to increase PPI in humans. It is unclear, however, whether the MDMA-induced increase in PPI in humans is also dependent on carrier-mediated serotonin release and which postsynaptic receptors are involved. We investigated the effects of three different pretreatments on the MDMA-induced effects on PPI and habituation in humans. Pretreatments were: (1) the highly selective serotonin uptake inhibitor citalopram (40 mg IV) in 16 subjects, (2) the D(2) antagonist haloperidol (1.4 mg IV) in 14 subjects, and (3) the 5-HT(2A/C) antagonist ketanserin (50 mg PO) in 14 subjects. Each of the three studies used a double-blind placebo-controlled design. All healthy volunteers were examined four times at 2-4-week intervals after placebo, pretreatment, MDMA (1.5 mg/kg PO), and pretreatment plus MDMA. MDMA increased PPI. Habituation was not altered by MDMA, although MDMA-induced individual differences on habituation and psychological symptoms were inversely correlated. Citalopram attenuated the MDMA-induced increase in PPI and most of the psychological effects of MDMA. Neither haloperidol nor ketanserin had any effect on PPI increases produced by MDMA, although each partially attenuated some MDMA-induced psychological effects. Results are consistent with the view that MDMA increases PPI of the acoustic startle reflex in humans via release of presynaptic serotonin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166515     DOI: 10.1016/S0893-133X(00)00199-8

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  23 in total

1.  Sensorimotor gating in mice is disrupted after AM404, an anandamide reuptake and degradation inhibitor.

Authors:  Emilio Fernandez-Espejo; Beatriz Galan-Rodriguez
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

2.  Initial deficit and recovery of function after MDMA preexposure in rats.

Authors:  K A Brennan; S Schenk
Journal:  Psychopharmacology (Berl)       Date:  2005-12-16       Impact factor: 4.530

3.  MDMA effects consistent across laboratories.

Authors:  Matthew G Kirkpatrick; Matthew J Baggott; John E Mendelson; Gantt P Galloway; Matthias E Liechti; Cédric M Hysek; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2014-03-15       Impact factor: 4.530

4.  Intimate insight: MDMA changes how people talk about significant others.

Authors:  Matthew J Baggott; Matthew G Kirkpatrick; Gillinder Bedi; Harriet de Wit
Journal:  J Psychopharmacol       Date:  2015-04-28       Impact factor: 4.153

5.  Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart.

Authors:  A M Peiró; M Farré; P N Roset; M Carbó; M Pujadas; M Torrens; J Camí; R de la Torre
Journal:  Psychopharmacology (Berl)       Date:  2012-11-10       Impact factor: 4.530

6.  Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats.

Authors:  Charles W Schindler; Eric B Thorndike; Bruce E Blough; Srihari R Tella; Steven R Goldberg; Michael H Baumann
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

7.  Additive Effects of Former Methylenedioxymethamphetamine and Cannabis Use on Subclinical Psychotic Symptoms.

Authors:  Berker Duman; Nilay Sedes; Bora Baskak
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

8.  Startle reactivity in children at risk for migraine.

Authors:  Roman Duncko; Lihong Cui; Jeffrey Hille; Christian Grillon; Kathleen R Merikangas
Journal:  Clin Neurophysiol       Date:  2008-10-31       Impact factor: 3.708

9.  Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.

Authors:  Onica Legendre; Stevan Pecic; Sandeep Chaudhary; Sarah M Zimmerman; William E Fantegrossi; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2009-11-20       Impact factor: 2.823

10.  Effect of apomorphine on cognitive performance and sensorimotor gating in humans.

Authors:  Arnt F A Schellekens; K P Grootens; C Neef; Kris L L Movig; J K Buitelaar; B Ellenbroek; R J Verkes
Journal:  Psychopharmacology (Berl)       Date:  2009-10-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.